{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:15:11Z","timestamp":1759601711589},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To compare pharmacy-prepared nicardipine and premade clevidipine with regard to time to goal systolic blood pressure (SBP) in acute cerebrovascular accident (CVA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, observational study was conducted comparing patients with acute CVA who received nicardipine or clevidipine. The primary objective was time to goal SBP. Secondary objectives included time from order to administration, time from administration to goal SBP, percentage of SBP readings below goal, total volume administered, hospital and intensive care unit lengths of stay, inpatient mortality and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-one patients were included in the study, 37 in the nicardipine group and 34 in the clevidipine group. A significant difference was found in mean time to goal SBP (150.9 minutes in the nicardipine group vs 69.3 minutes in the clevidipine group, P &amp;lt; 0.01). Time from order to administration was 80.1 minutes in the nicardipine group and 35.2 minutes in the clevidipine group (P &amp;lt; 0.01). Mean time from administration to goal SBP was 70.9 minutes in the nicardipine group and 42.3 minutes in the clevidipine group (P = 0.02). There was no difference between groups in percentage of SBP readings below goal, total volume administered, length of stay, or inpatient mortality. Adverse events occurred in 13 (35.1%) of the nicardipine-treated patients and 17 (50%) of the clevidipine-treated patients (P = 0.42).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Compared to use of pharmacy-prepared nicardipine, use of premade clevidipine was associated with a shorter time to goal SBP in patients with acute CVA. There were no significant between-group differences in safety outcomes. Premade clevidipine should be considered over pharmacy-prepared nicardipine when rapid blood pressure lowering is warranted in acute CVA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab394","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T20:30:59Z","timestamp":1634502659000},"page":"e110-e116","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of premade clevidipine and pharmacy-prepared nicardipine in time to goal systolic blood pressure in acute cerebrovascular accident"],"prefix":"10.1093","volume":"79","author":[{"given":"Bethany E","family":"Martini","sequence":"first","affiliation":[{"name":"St. Joseph Mercy Livingston, Howell, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber L","family":"Schalk","sequence":"additional","affiliation":[{"name":"Sparrow Hospital, Lansing, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"2022041907570169700_CIT0001","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/ACO.0b013e32835721a5","article-title":"Blood pressure management in stroke","volume":"25","author":"Donovan","year":"2012","journal-title":"Curr Opin Anaesthesiol"},{"key":"2022041907570169700_CIT0002","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.02.015","article-title":"Antihypertensives are administered selectively in emergency department patients with subarachnoid hemorrhage","volume":"22","author":"Culyer","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2022041907570169700_CIT0003","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.119.027708","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke","volume":"50","author":"Warner","year":"2019","journal-title":"Stroke"},{"key":"2022041907570169700_CIT0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2008.04.025","article-title":"Clevidipine, an intravenous dihydropryidine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension","volume":"53","author":"Pollack","year":"2009","journal-title":"Ann Emerg Med"},{"key":"2022041907570169700_CIT0005","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1213\/ane.0b013e31818240db","article-title":"The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients","volume":"107","author":"Aronson","year":"2008","journal-title":"Anesth Analg"},{"key":"2022041907570169700_CIT0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000351149","article-title":"Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial","volume":"36","author":"Graffagnino","year":"2013","journal-title":"Cerebrovasc Dis"},{"key":"2022041907570169700_CIT0007","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12028-016-0349-4","article-title":"Clevidipine versus nicardipine for acute blood pressure reduction in a neuroscience intensive care population","volume":"26","author":"Finger","year":"2017","journal-title":"Neurocrit Care"},{"key":"2022041907570169700_CIT0008","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/0885066617724340","article-title":"Comparison of clevidipine and nicardipine for acute blood pressure reduction in patients with stroke","volume":"34","author":"Allison","year":"2019","journal-title":"J Intensive Care Med"},{"key":"2022041907570169700_CIT0009","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.03.001","article-title":"Comparison of nicardipine with clevidipine in the management of hypertension in acute cerebrovascular diseases","volume":"27","author":"Rosenfeldt","year":"2018","journal-title":"J Stroke Cerebrovasc Dis."},{"volume-title":"Lexicomp Online [proprietary data]","year":"2020","author":"Clevidipine.","key":"2022041907570169700_CIT0010"},{"volume-title":"Lexicomp Online [proprietary data]","year":"2020","author":"Nicardipine.","key":"2022041907570169700_CIT0011"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab394\/40927517\/zxab394.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/9\/e110\/43387615\/zxab394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/9\/e110\/43387615\/zxab394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T08:16:11Z","timestamp":1650356171000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/9\/e110\/6390797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":11,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,10,12]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab394","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,10,12]]}}}